日本创新药物研发激励政策及对我国的启示——基于依达拉奉研发的实证分析  

Research on incentive policies of innovative drugs in Japan and its enlightenment to China—an empirical study on research and development of edaravone

作　　者：丁锦希[1] 孟立立[1] 罗茜玮[1] 

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198

出　　处：《中国新药与临床杂志》2011年第11期839-847,共9页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家社会科学基金项目(10CFX055);国家知识产权局软科学研究项目(SS09-A-26);江苏省科技厅软科学研究项目(BR20100060)

摘　　要：本研究意在为完善我国创新药物研发激励政策提供借鉴并提出建议。通过简要分析日本创新药物研发各项激励政策,并以日本重大创新药物依达拉奉为实证研究对象,采用个案剖析的方法,深入探讨激励政策对创新药物研发的激励机制及实施绩效。结果表明,日本创新政策对该国的创新药物研发起到了极大的促进和激励作用。我国应借鉴日本的成功经验,积极调整和完善相关创新药物研发激励政策。This study aims at providing specific reference and guidance to improve incentive policies on innovative drugs in our country. Based on a brief analysis of the incentive policies on the innovative drugs in Japan, this study deeply explores the mechanism as well as the performance of the implementation of the incentive policies, utilizing the case analysis method and taking the innovative drug edaravone as an example. The result shows that the series of incentive policies adopted by Japan had greatly promoted its research and development. The successful experience of Japan should be introduced to improve and perfect the research and development of incentive policies on innovative drugs in our country.

关 键 词：制药工业 政策制定 依达拉奉 创新药物 激励政策 实证分析 

分 类 号：R971[医药卫生—药品]